1-2 of 2
Susan G. Hilsenbeck
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted Treatment

Open Access
Beom-Jun Kim, Ze-Yi Zheng, Jonathan T. Lei, Matthew V. Holt, Anran Chen, Jianheng Peng, Diana Fandino, Purba Singh, Hilda Kennedy, Yongchao Dou, María del Rosario Chica-Parrado, Emmanuel Bikorimana, Dan Ye, Yunguan Wang, Ariella B. Hanker, Nada Mohamed, Susan G. Hilsenbeck, Bora Lim, Jaya Ruth Asirvatham, Arun Sreekumar, Bing Zhang, George Miles, Meenakshi Anurag, Matthew J. Ellis, Eric C. Chang
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (7): 1366–1377.
https://doi.org/10.1158/2767-9764.CRC-23-0044
Published: 26 July 2023
View articletitled, Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted Treatment
Open the PDF for Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted Treatment in another window
Includes: Supplementary data
Journal Articles

Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics

Open Access
Yang Gao, Elena B. Kabotyanski, Jonathan H. Shepherd, Elizabeth Villegas, Deanna Acosta, Clark Hamor, Tingting Sun, Celina Montmeyor-Garcia, Xiaping He, Lacey E. Dobrolecki, Thomas F. Westbrook, Michael T. Lewis, Susan G. Hilsenbeck, Xiang H.-F. Zhang, Charles M. Perou, Jeffrey M. Rosen
Journal: Cancer Research Communications
Cancer Research Communications (2021) 1 (3): 178–193.
https://doi.org/10.1158/2767-9764.CRC-21-0106
Published: 27 December 2021
View articletitled, Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics
Open the PDF for Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics in another window
Includes: Supplementary data